Switching GLP-1 Medications: When and How

Switching agents is one of the most common and least discussed decisions in GLP-1 therapy. It is usually prompted by one of three things — a plateau, intolerable side effects, or cost — and the right answer differs substantially depending on which.

How We Assessed These

Match the reason for switching to the agent you switch to. These are the situations and what they point toward.

Switching for Efficacy

This is the most common reason, and the direction is usually semaglutide to tirzepatide. Tirzepatide leads on weight reduction at above 20% in pivotal trials versus roughly 14.9% for injectable semaglutide, and clinicians report switching restarting progress for many plateaued patients.

Before switching, confirm the plateau is real. Trial data show plateaus are an expected endpoint — mean time to plateau with tirzepatide was 4.4 and 6.7 weeks longer at 10 mg and 15 mg respectively compared with 5 mg. If you plateaued below the maximum dose of your current agent, escalating may be the simpler answer than switching.

Switching for Tolerability

Tolerability genuinely varies between molecules, and a patient intolerant of one GLP-1 may do well on another. But before switching, the more effective adjustments are often slower titration or a lower maintenance dose — extending time at each step is the most underused intervention in this class.

If gastrointestinal symptoms are severe rather than merely unpleasant — persistent vomiting, inability to maintain hydration, vomiting undigested food hours later — that warrants evaluation rather than a switch.

Switching for Cost or Route

The 2026 price changes opened a route that did not previously exist. Foundayo (orforglipron) entered at roughly $149/month self-pay at the starting dose, with a $50/month rate for eligible Medicare Part D beneficiaries from July 2026.

The trade is efficacy: orforglipron reached 12.4% at the highest dose in ATTAIN-1, below both semaglutide formulations and well below tirzepatide. For a patient who would otherwise stop entirely because of cost, that is a good trade — given that discontinuation typically reverses most of the result. For a patient doing well on a stronger agent with manageable cost, it is not.

Questions Worth Asking Before You Enrol

• Is my plateau real, or should we escalate my current dose first?
• Would slower titration fix my side effects without switching?
• What dose would I start at on the new agent?
• Should I expect a gap between stopping one and starting the other?
• Does the new agent still fit my indication and coverage?

A provider that answers these clearly is managing a treatment plan. One that deflects to a monthly price is selling a subscription.